JP2012121878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012121878A5 JP2012121878A5 JP2011207654A JP2011207654A JP2012121878A5 JP 2012121878 A5 JP2012121878 A5 JP 2012121878A5 JP 2011207654 A JP2011207654 A JP 2011207654A JP 2011207654 A JP2011207654 A JP 2011207654A JP 2012121878 A5 JP2012121878 A5 JP 2012121878A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- antigen
- binding fragment
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (13)
- モノクローナル抗ＣＳ１抗体または抗ＣＳ１抗原結合フラグメントを含む、多発性骨髄腫を治療するための医薬組成物であって、前記モノクローナル抗ＣＳ１抗体または前記抗ＣＳ１抗原結合フラグメントは、配列番号１によってコードされるタンパク質に結合する、前記医薬組成物。
- コンジュゲート化合物を含有する、多発性骨髄腫を治療するための医薬組成物であって、前記コンジュゲート化合物は、エフェクター部分に連結されているモノクローナル抗ＣＳ１抗体または抗ＣＳ１抗原結合フラグメントを含み、前記モノクローナル抗ＣＳ１抗体または前記抗ＣＳ１抗原結合フラグメントは、配列番号１によってコードされるタンパク質に結合する、前記医薬組成物。
- 前記モノクローナル抗ＣＳ１抗体または前記抗ＣＳ１抗原結合フラグメントは、免疫グロブリン分泌を阻害する、請求項１または２に記載の医薬組成物。
- 前記モノクローナル抗ＣＳ１抗体または前記抗ＣＳ１抗原結合フラグメントは、ヒト化されている、請求項１または２に記載の医薬組成物。
- 前記モノクローナル抗ＣＳ１抗体または前記抗ＣＳ１抗原結合フラグメントは、配列番号１によってコードされるタンパク質を発現する細胞について、抗体由来細胞傷害性（ＡＤＣＣ）を誘導する、請求項１または２に記載の医薬組成物。
- 前記モノクローナル抗ＣＳ１抗体または前記抗ＣＳ１抗原結合フラグメントは、配列番号１によってコードされるタンパク質を発現する細胞について、少なくとも４０％の細胞傷害性を誘導する、請求項１または２に記載の医薬組成物。
- 前記モノクローナル抗ＣＳ１抗体または前記抗ＣＳ１抗原結合フラグメントは、配列番号１によってコードされるタンパク質を発現する細胞について、少なくとも６０％の細胞傷害性を誘導する、請求項１または２に記載の医薬組成物。
- 前記モノクローナル抗ＣＳ１抗体または前記抗ＣＳ１抗原結合フラグメントは、ＩｇＧ１である、請求項１または２に記載の医薬組成物。
- 前記モノクローナル抗ＣＳ１抗体または前記抗ＣＳ１抗原結合フラグメントは、低レベルのフコースを有するか、フコースを欠く、請求項１または２に記載の医薬組成物。
- １つ以上の免疫抑制薬および免疫調節薬の後に投与される、または１つ以上の免疫抑制薬および免疫調節薬と組み合わせて投与される、請求項１〜９のいずれか１項に記載の医薬組成物。
- 免疫調節薬の後に投与される、または免疫調節薬と組み合わせて投与される、請求項１〜９のいずれか１項に記載の医薬組成物。
- 前記エフェクター部分は、細胞傷害性薬剤である、請求項２に記載の医薬組成物。
- 前記エフェクター部分は、検出部分、活性化可能な部分、化学療法薬、リパーゼ、抗生物質、化学誘因部分、免疫調節物質、または放射性同位体である、請求項２に記載の医薬組成物。
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46921103P | 2003-05-08 | 2003-05-08 | |
| US60/469,211 | 2003-05-08 | ||
| US55762204P | 2004-03-29 | 2004-03-29 | |
| US55762104P | 2004-03-29 | 2004-03-29 | |
| US55762004P | 2004-03-29 | 2004-03-29 | |
| US60/557,621 | 2004-03-29 | ||
| US60/557,622 | 2004-03-29 | ||
| US60/557,620 | 2004-03-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532992A Division JP4887152B2 (ja) | 2003-05-08 | 2004-05-10 | 抗ｃｓ１抗体の治療的使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014030549A Division JP6042834B2 (ja) | 2003-05-08 | 2014-02-20 | 抗ｃｓ１抗体の治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012121878A JP2012121878A (ja) | 2012-06-28 |
| JP2012121878A5 true JP2012121878A5 (ja) | 2012-11-08 |
| JP5976288B2 JP5976288B2 (ja) | 2016-08-23 |
Family
ID=33459144
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532992A Expired - Lifetime JP4887152B2 (ja) | 2003-05-08 | 2004-05-10 | 抗ｃｓ１抗体の治療的使用 |
| JP2011207654A Expired - Lifetime JP5976288B2 (ja) | 2003-05-08 | 2011-09-22 | 抗ｃｓ１抗体の治療的使用 |
| JP2014030549A Expired - Lifetime JP6042834B2 (ja) | 2003-05-08 | 2014-02-20 | 抗ｃｓ１抗体の治療的使用 |
| JP2016142300A Pending JP2017019795A (ja) | 2003-05-08 | 2016-07-20 | 抗ｃｓ１抗体の治療的使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532992A Expired - Lifetime JP4887152B2 (ja) | 2003-05-08 | 2004-05-10 | 抗ｃｓ１抗体の治療的使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014030549A Expired - Lifetime JP6042834B2 (ja) | 2003-05-08 | 2014-02-20 | 抗ｃｓ１抗体の治療的使用 |
| JP2016142300A Pending JP2017019795A (ja) | 2003-05-08 | 2016-07-20 | 抗ｃｓ１抗体の治療的使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US20050025763A1 (ja) |
| EP (4) | EP2371391B1 (ja) |
| JP (4) | JP4887152B2 (ja) |
| KR (1) | KR101268707B1 (ja) |
| CN (1) | CN1805755B (ja) |
| AT (1) | ATE506076T1 (ja) |
| AU (2) | AU2004238363B2 (ja) |
| BE (1) | BE2016C056I2 (ja) |
| BR (1) | BRPI0410129B8 (ja) |
| CA (1) | CA2523001C (ja) |
| CY (4) | CY1111958T1 (ja) |
| DE (1) | DE602004032328D1 (ja) |
| DK (3) | DK2371391T3 (ja) |
| ES (2) | ES2516840T3 (ja) |
| FR (1) | FR16C1012I2 (ja) |
| HK (3) | HK1089374A1 (ja) |
| HU (2) | HUE034908T2 (ja) |
| LT (1) | LT2853272T (ja) |
| LU (1) | LU93274I2 (ja) |
| MX (1) | MXPA05012011A (ja) |
| NL (1) | NL300838I2 (ja) |
| PL (3) | PL1624892T3 (ja) |
| PT (3) | PT1624892E (ja) |
| SI (3) | SI2371391T1 (ja) |
| WO (1) | WO2004100898A2 (ja) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| DK2068930T3 (da) * | 2006-08-07 | 2012-10-29 | Abbott Biotherapeutics Corp | Sammensætninger og fremgangsmåder under anvendelse af anti-CS1-antistoffer til at behandle multiple myelomer |
| NZ574978A (en) | 2006-08-07 | 2012-08-31 | Dana Farber Cancer Inst Inc | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
| EP2069478A2 (en) * | 2006-08-07 | 2009-06-17 | PDL BioPharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| EP3384919A1 (en) | 2008-06-02 | 2018-10-10 | Dana Farber Cancer Institute, Inc. | Cs1 peptides |
| BRPI0921433A2 (pt) * | 2008-10-31 | 2017-06-06 | Abbott Biotherapeutics Corp | uso de anticorpos anti-cs1 para o tratamento de linfomas raros |
| SG10201500705YA (en) * | 2009-01-08 | 2015-04-29 | Bio Rad Laboratories | Methods and compositions for improving efficiency of nucleic acids amplification reactions |
| WO2011060076A1 (en) * | 2009-11-10 | 2011-05-19 | Amgen Inc. | Anti-c-mpl antibodies |
| UA104663C2 (en) | 2010-01-28 | 2014-02-25 | Глаксо Груп Лимитед | Antibody binding to cd127 |
| CN105777907B (zh) | 2010-02-24 | 2020-03-17 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| RS56916B1 (sr) | 2011-04-01 | 2018-05-31 | Immunogen Inc | Postupci za povećanje efikasnosti terapije kancera usmerene na folr1 |
| ES2788151T3 (es) | 2012-08-31 | 2020-10-20 | Immunogen Inc | Kits y ensayos de diagnóstico para la detección del receptor 1 de folato |
| EP3919069A1 (en) | 2012-11-05 | 2021-12-08 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| EP2970436B1 (en) * | 2013-03-15 | 2018-09-05 | AbbVie Biotherapeutics Inc. | Fc variants |
| CN105377892A (zh) * | 2013-03-15 | 2016-03-02 | 艾伯维生物技术有限公司 | 抗cd25抗体及其用途 |
| EP2992020B1 (en) * | 2013-05-03 | 2020-01-15 | Ohio State Innovation Foundation | Cs1-specific chimeric antigen receptor engineered immune effector cells |
| US20160159918A1 (en) * | 2013-07-24 | 2016-06-09 | The General Hospital Corporation | Methods for diagnosing and treating immune disease |
| JP2016536330A (ja) | 2013-08-30 | 2016-11-24 | イミュノジェン， インコーポレイテッド | 葉酸受容体１の検出用の抗体及びアッセイ |
| US9482289B2 (en) | 2013-10-14 | 2016-11-01 | Club Car, Llc | Self-preloading shift lever |
| EP3066128B1 (en) | 2013-11-06 | 2018-10-31 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| US20160264670A1 (en) | 2013-11-06 | 2016-09-15 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| US20170051037A1 (en) * | 2014-05-02 | 2017-02-23 | Cellectis | Cs1 specific multi-chain chimeric antigen receptor |
| PL3157561T3 (pl) * | 2014-06-17 | 2020-06-29 | Medimmune Limited | Ulepszone przeciwciała alfa-v beta-8 |
| AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| WO2016049022A1 (en) * | 2014-09-23 | 2016-03-31 | Board Of Trustees Of Michigan State University | Compositions and methods for modulating an immune response |
| WO2016070089A2 (en) * | 2014-10-31 | 2016-05-06 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| EP3227335A1 (en) | 2014-12-04 | 2017-10-11 | Bristol-Myers Squibb Company | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
| DE102015102183B4 (de) * | 2015-02-16 | 2018-03-01 | Robert Bosch Automotive Steering Gmbh | Lenkzwischenwelle für ein Kraftfahrzeug und Verfahren zum Betreiben einer Lenkzwischenwelle für ein Kraftfahrzeug |
| WO2016134371A2 (en) | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| WO2016168766A1 (en) * | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized chimeric receptor t cell switches and uses thereof |
| SI3313528T1 (sl) | 2015-06-29 | 2021-11-30 | Bristol-Myers Squibb Company | Imunoterapevtski režim odmerjanja, ki vsebujejo pomalidomid in protitelo anti-CS1 za zdravljenje raka |
| MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| MA42844A (fr) | 2015-09-17 | 2018-07-25 | Immunogen Inc | Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1 |
| EP4046655A1 (en) * | 2015-11-03 | 2022-08-24 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| RU2019132201A (ru) | 2017-03-13 | 2021-04-14 | ИНТРИНСИК ЛАЙФСАЙЕНСИС ЭлЭлСи | Антитела к человеческому эритроферрону и их применение |
| WO2018182529A1 (en) * | 2017-03-29 | 2018-10-04 | Agency For Science, Technology And Research | Anti oligosaccharide antibody |
| HUE053760T2 (hu) | 2017-06-20 | 2021-07-28 | Inst Curie | SUV39h1-deficiens immunsejtek |
| CN111133002B (zh) * | 2017-08-07 | 2024-05-24 | 恩比伊治疗股份公司 | 具有高体内耐受性的基于蒽环类药的抗体药物缀合物 |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| EP3704229B1 (en) | 2017-11-01 | 2023-12-20 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| CN111511370A (zh) | 2017-11-01 | 2020-08-07 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体 |
| MX2020004240A (es) | 2017-11-01 | 2020-09-25 | Juno Therapeutics Inc | Proceso para generar composiciones terapeuticas de celulas modificadas. |
| KR20200116077A (ko) | 2017-11-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드 |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| AU2018379094A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
| WO2019113556A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| JP2021505168A (ja) | 2017-12-08 | 2021-02-18 | ジュノー セラピューティクス インコーポレイテッド | 操作されたｔ細胞の組成物を製造するための方法 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| AU2019232631A1 (en) | 2018-03-05 | 2020-09-24 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
| WO2020002579A1 (en) | 2018-06-29 | 2020-01-02 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Tweak-receptor agonists for use in combination with immunotherapy of a cancer |
| CN112805378A (zh) | 2018-08-09 | 2021-05-14 | 朱诺治疗学股份有限公司 | 用于评估整合核酸的方法 |
| CN109406798A (zh) * | 2018-10-29 | 2019-03-01 | 美康生物科技股份有限公司 | 肌酐酶法检测试剂盒 |
| WO2020092854A2 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| WO2020092848A2 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| IL263394A (en) * | 2018-11-29 | 2020-05-31 | Amit Ido | Methods for activating inactive immune cells and cancer treatment |
| SG11202111360YA (en) | 2019-05-01 | 2021-11-29 | Juno Therapeutics Inc | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| US20220218750A1 (en) | 2019-05-01 | 2022-07-14 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| JP2022542102A (ja) | 2019-07-23 | 2022-09-29 | ムネモ・セラピューティクス | Ｓｕｖ３９ｈ１欠損免疫細胞 |
| KR20220092578A (ko) | 2019-11-05 | 2022-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | M-단백질 검정 및 이의 용도 |
| IL295258A (en) * | 2020-02-05 | 2022-10-01 | Navaux Inc | Anti-hepsin antibodies and uses thereof |
| CA3179800A1 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
| EP4150640A1 (en) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| WO2022023576A1 (en) | 2020-07-30 | 2022-02-03 | Institut Curie | Immune cells defective for socs1 |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| US20240108654A1 (en) | 2021-03-03 | 2024-04-04 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
| US20240269282A1 (en) | 2021-05-10 | 2024-08-15 | Institut Curie | Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases |
| WO2022248602A1 (en) | 2021-05-25 | 2022-12-01 | Institut Curie | Myeloid cells overexpressing bcl2 |
| WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
| WO2023159182A1 (en) | 2022-02-18 | 2023-08-24 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
| WO2023187024A1 (en) | 2022-03-31 | 2023-10-05 | Institut Curie | Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| WO2024114691A1 (en) * | 2022-12-02 | 2024-06-06 | Guangzhou Litai Biotechnology Co., Ltd. | Human cs1 car-t cells |
| WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
| WO2024161021A1 (en) | 2023-02-03 | 2024-08-08 | Juno Therapeutics Gmbh | Methods for non-viral manufacturing of engineered immune cells |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5004692A (en) | 1987-12-15 | 1991-04-02 | Protein Design Labs, Inc. | Cloning and expression of phosopholipase C genes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| KR0162259B1 (ko) | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
| US20020099179A1 (en) * | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
| JPH07101999A (ja) * | 1993-10-06 | 1995-04-18 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列 |
| US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| WO1996039518A1 (en) | 1995-06-05 | 1996-12-12 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefor |
| US6607898B1 (en) * | 1996-03-26 | 2003-08-19 | Oncomedx, Inc. | Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum |
| WO1999063088A2 (en) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Membrane-bound proteins and nucleic acids encoding the same |
| JP2001522239A (ja) * | 1997-03-21 | 2001-11-13 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | ８７個のヒト分泌タンパク質 |
| WO2000011150A1 (en) | 1998-08-25 | 2000-03-02 | Incyte Pharmaceuticals, Inc. | Cell surface immunomodulators |
| AU2757500A (en) | 1999-02-10 | 2000-08-29 | Human Genome Sciences, Inc. | 33 human secreted proteins |
| CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| US7465785B2 (en) * | 1999-03-08 | 2008-12-16 | Genentech, Inc. | Polypeptide encoded by a nucleic acid over-expressed in melanoma |
| WO2000055627A1 (en) | 1999-03-15 | 2000-09-21 | Eos Biotechnology, Inc. | Reusable low fluorescent plastic biochip |
| CA2383254A1 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP3951035B2 (ja) | 1999-09-01 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 分泌及び膜貫通ポリペプチドとそれをコードしている核酸 |
| WO2001046260A2 (en) * | 1999-12-23 | 2001-06-28 | Bristol-Myers Squibb Company | Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof |
| AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2004500108A (ja) * | 2000-03-24 | 2004-01-08 | マイクロメット アーゲー | Ｎｋｇ２ｄレセプター複合体のエピトープへの結合部位を含む多機能ポリペプチド |
| EP1283721A4 (en) | 2000-05-26 | 2004-07-07 | Smithkline Beecham Corp | ANTI-RANK-LIGAND-BINDING MONOCLONAL ANTIBODIES USEFUL FOR TREATING DISEASES CAUSED BY THE RANK-LIGANDS |
| US6410271B1 (en) | 2000-06-23 | 2002-06-25 | Genetastix Corporation | Generation of highly diverse library of expression vectors via homologous recombination in yeast |
| BR0206985A (pt) * | 2001-01-29 | 2005-04-19 | Idec Pharma Corp | Anticorpos modificados e métodos de uso |
| CA2441832A1 (en) | 2001-03-21 | 2002-12-27 | Human Genome Sciences, Inc. | Human secreted proteins |
| US20030099974A1 (en) * | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| WO2003018621A2 (en) | 2001-08-23 | 2003-03-06 | Oxford Biomedica (Uk) Limited | Genes |
| US20040038877A1 (en) | 2001-10-02 | 2004-02-26 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US6478825B1 (en) * | 2001-11-28 | 2002-11-12 | Osteotech, Inc. | Implant, method of making same and use of the implant for the treatment of bone defects |
| US7041499B2 (en) * | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| ATE541857T1 (de) | 2002-09-27 | 2012-02-15 | Xencor Inc | Optimierte fc-varianten und herstellungsverfahren dafür |
| US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| BRPI0921433A2 (pt) | 2008-10-31 | 2017-06-06 | Abbott Biotherapeutics Corp | uso de anticorpos anti-cs1 para o tratamento de linfomas raros |
| KR102028770B1 (ko) | 2011-09-15 | 2019-10-04 | 컨버전트 인포메이션 테크놀로지스 게엠베하 | 로봇 프로그램의 자동 생성을 위한 시스템 및 방법 |
| ES2741897T3 (es) | 2012-02-13 | 2020-02-12 | Radius Eng Inc | Cartucho reutilizable para moldeo por inyección |
-
2004
- 2004-05-07 US US10/842,011 patent/US20050025763A1/en not_active Abandoned
- 2004-05-10 LT LTEP14178061.9T patent/LT2853272T/lt unknown
- 2004-05-10 EP EP10183377.0A patent/EP2371391B1/en not_active Expired - Lifetime
- 2004-05-10 BR BRPI0410129A patent/BRPI0410129B8/pt active IP Right Grant
- 2004-05-10 DK DK10183377.0T patent/DK2371391T3/da active
- 2004-05-10 PL PL04760993T patent/PL1624892T3/pl unknown
- 2004-05-10 PT PT04760993T patent/PT1624892E/pt unknown
- 2004-05-10 PL PL10183377T patent/PL2371391T3/pl unknown
- 2004-05-10 SI SI200432193T patent/SI2371391T1/sl unknown
- 2004-05-10 HU HUE14178061A patent/HUE034908T2/hu unknown
- 2004-05-10 MX MXPA05012011A patent/MXPA05012011A/es active IP Right Grant
- 2004-05-10 SI SI200432408T patent/SI2853272T1/sl unknown
- 2004-05-10 WO PCT/US2004/014866 patent/WO2004100898A2/en active Application Filing
- 2004-05-10 EP EP14178061.9A patent/EP2853272B1/en not_active Expired - Lifetime
- 2004-05-10 AT AT04760993T patent/ATE506076T1/de active
- 2004-05-10 ES ES10183377.0T patent/ES2516840T3/es not_active Expired - Lifetime
- 2004-05-10 PT PT141780619T patent/PT2853272T/pt unknown
- 2004-05-10 DK DK14178061.9T patent/DK2853272T3/da active
- 2004-05-10 JP JP2006532992A patent/JP4887152B2/ja not_active Expired - Lifetime
- 2004-05-10 DK DK04760993.8T patent/DK1624892T3/da active
- 2004-05-10 CA CA2523001A patent/CA2523001C/en not_active Expired - Lifetime
- 2004-05-10 EP EP04760993A patent/EP1624892B1/en not_active Expired - Lifetime
- 2004-05-10 AU AU2004238363A patent/AU2004238363B2/en not_active Expired
- 2004-05-10 SI SI200431707T patent/SI1624892T1/sl unknown
- 2004-05-10 DE DE602004032328T patent/DE602004032328D1/de not_active Expired - Lifetime
- 2004-05-10 EP EP17176948.2A patent/EP3275463A1/en not_active Withdrawn
- 2004-05-10 CN CN2004800164542A patent/CN1805755B/zh not_active Expired - Lifetime
- 2004-05-10 ES ES14178061.9T patent/ES2643289T3/es not_active Expired - Lifetime
- 2004-05-10 PT PT101833770T patent/PT2371391E/pt unknown
- 2004-05-10 PL PL14178061T patent/PL2853272T3/pl unknown
-
2005
- 2005-11-07 KR KR1020057021141A patent/KR101268707B1/ko active IP Right Grant
-
2006
- 2006-09-05 HK HK06109846.1A patent/HK1089374A1/xx not_active IP Right Cessation
-
2009
- 2009-03-10 US US12/401,531 patent/US20090238827A1/en not_active Abandoned
- 2009-03-10 US US12/401,513 patent/US8133981B2/en not_active Expired - Lifetime
- 2009-11-02 US US12/610,899 patent/US8008450B2/en not_active Expired - Lifetime
-
2010
- 2010-08-25 AU AU2010214661A patent/AU2010214661B2/en not_active Expired
-
2011
- 2011-06-30 US US13/174,134 patent/US8445646B2/en not_active Expired - Lifetime
- 2011-07-14 CY CY20111100687T patent/CY1111958T1/el unknown
- 2011-09-22 JP JP2011207654A patent/JP5976288B2/ja not_active Expired - Lifetime
-
2012
- 2012-04-05 HK HK12103383.5A patent/HK1163497A1/xx not_active IP Right Cessation
-
2013
- 2013-05-15 US US13/894,857 patent/US9175081B2/en not_active Expired - Lifetime
-
2014
- 2014-02-20 JP JP2014030549A patent/JP6042834B2/ja not_active Expired - Lifetime
- 2014-10-23 CY CY20141100872T patent/CY1115671T1/el unknown
-
2015
- 2015-09-22 US US14/860,906 patent/US10442859B2/en active Active
- 2015-09-29 HK HK15109572.0A patent/HK1208815A1/xx unknown
-
2016
- 2016-07-20 JP JP2016142300A patent/JP2017019795A/ja active Pending
- 2016-10-20 HU HUS1600042C patent/HUS1600042I1/hu unknown
- 2016-10-24 BE BE2016C056C patent/BE2016C056I2/fr unknown
- 2016-10-24 LU LU93274C patent/LU93274I2/fr unknown
- 2016-10-25 NL NL300838C patent/NL300838I2/nl unknown
- 2016-10-26 CY CY2016035C patent/CY2016035I2/el unknown
- 2016-10-27 FR FR16C1012C patent/FR16C1012I2/fr active Active
-
2017
- 2017-09-15 CY CY20171100980T patent/CY1119353T1/el unknown
-
2019
- 2019-10-10 US US16/599,035 patent/US20200031929A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012121878A5 (ja) | ||
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| JP2012521217A5 (ja) | ||
| RU2020120539A (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
| JP2013198490A5 (ja) | ||
| JP2012034692A5 (ja) | ||
| HRP20170342T1 (hr) | Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice | |
| JP2014205674A5 (ja) | ||
| JP2014526898A5 (ja) | ||
| HRP20192295T1 (hr) | Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi) | |
| JP2017514461A5 (ja) | ||
| JP2012116856A5 (ja) | ||
| JP2011157378A5 (ja) | ||
| JP2012102122A5 (ja) | ||
| JP2009225799A5 (ja) | ||
| JP2010500371A5 (ja) | ||
| JP2017507936A5 (ja) | ||
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2016512425A5 (ja) | ||
| JP2013231054A5 (ja) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2015533795A5 (ja) | ||
| NZ602040A (en) | Anti-lrp6 antibodies | |
| JP2008540447A5 (ja) | ||
| JP2011157403A5 (ja) |